Evaluating NeoGenomics: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
NeoGenomics (NASDAQ:NEO) received mixed ratings from 4 analysts, with an average 12-month price target of $21.25, reflecting a 6.26% decline from the previous target. The company, specializing in cancer-focused genetic testing, shows a revenue growth of 17.99% but struggles with profitability, having a net margin of -12.19% and ROE of -1.95%. Despite these challenges, its debt-to-equity ratio of 0.64 indicates a sound financial structure.
February 21, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NeoGenomics received mixed analyst ratings, with a revised average 12-month price target of $21.25, indicating a potential downside. The company's strong revenue growth contrasts with its profitability issues.
The mixed analyst ratings and the downward revision of the price target reflect uncertainty and potential concerns about NeoGenomics' future stock performance. Despite strong revenue growth, the company's profitability issues, such as a negative net margin and ROE, could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100